Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | RAD51 | Q06609 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449203 | 1.00 | PTPN1 (0.50) | PTPN1PTPN2RAD51KDM4EALDH1A1 | |
| SCHEMBL24329860 | 0.78 | NPM1 (0.43) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL830523 | 0.78 | KLK7 (0.43) | RAD51KDM4EALDH1A1GAAGLA | |
| SCHEMBL831947 | 0.78 | ALDH1A1 (0.46) | PTPN1RAD51KDM4EALDH1A1HPGD | |
| SCHEMBL10806873 | 0.75 | KDM4E (0.58) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL11884712 | 0.75 | PARP1 (0.44) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL12883857 | 0.75 | PARP1 (0.51) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL24329942 | 0.74 | BRD4 (0.39) | PTPN1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL3126879 | 0.72 | MAPT (0.55) | RAD51KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3118498 | 0.72 | MAPT (0.55) | KDM4EALDH1A1GAAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4167569-A | ANTICOAGULANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-09-11 | — | — | US | claimed |
| EP-3846811-B1 | COMBINATION OF APREPITANT, BUPIVACAINE, AND MELOXICAM FOR USE IN THE TREATMENT OF POST-SURGICAL PAIN | HERON THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12419861-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-23 | — | — | US | disclosed |
| EP-4598923-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | The Regents of the University of California (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3966215-B1 | SYNTHESIS OF LABELED IMIDAZO[1,2-A]PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2025-01-29 | — | — | EP | disclosed |
| US-12115255-B2 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | HERON THERAPEUTICS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-12115254-B2 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | HERON THERAPEUTICS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240238197-A1 | METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST | HERON THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12037332-B2 | Compound including benzimidazole ring structure and organic electroluminescent element | HODOGAYA CHEMICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| EP-1768200-A1 | Dopant and its production method | Novaled AG (DE) | 2007-03-28 | — | — | EP | disclosed |
| EP-1672714-A2 | Dopant and its production method | Novaled GmbH (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-20050277117-A1 | Drug discovery method | KEDDEM BIO-SCIENCE LTD. (IL) | 2005-12-15 | — | — | US | disclosed |
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1461035-A4 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1461035-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003053344-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| US-4167569-A | ANTICOAGULANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-09-11 | — | — | US | disclosed |
| US-4167569-A | ANTICOAGULANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | PTPN1 4528/4885PTPN2 4261/4885RAD51 290/4885 |
| US-12037332-B2 | Compound including benzimidazole ring structure and organic electroluminescent element | H1-0, H1-4, H1-2 | PTPN1 4435/4885PTPN2 4516/4885RAD51 1263/4885 |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | PTPN1 3627/4885PTPN2 2860/4885RAD51 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.